Brii Biosciences Management
Management criteria checks 3/4
Brii Biosciences' CEO is Zhi Hong, appointed in Feb 2018, has a tenure of 8.33 years. total yearly compensation is CN¥12.32M, comprised of 71.8% salary and 28.2% bonuses, including company stock and options. directly owns 4.68% of the company’s shares, worth $4.40M. The average tenure of the management team and the board of directors is 4.8 years and 5 years respectively.
Key information
Zhi Hong
Chief executive officer
CN¥12.3m
Total compensation
| CEO salary percentage | 71.76% |
| CEO tenure | 8.3yrs |
| CEO ownership | 4.7% |
| Management average tenure | 4.8yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | CN¥12m | CN¥9m | -CN¥223m |
| Sep 30 2025 | n/a | n/a | -CN¥299m |
| Jun 30 2025 | n/a | n/a | -CN¥376m |
| Mar 31 2025 | n/a | n/a | -CN¥442m |
| Dec 31 2024 | CN¥22m | CN¥12m | -CN¥508m |
| Sep 30 2024 | n/a | n/a | -CN¥387m |
| Jun 30 2024 | n/a | n/a | -CN¥265m |
| Mar 31 2024 | n/a | n/a | -CN¥220m |
| Dec 31 2023 | CN¥18m | CN¥7m | -CN¥175m |
| Sep 30 2023 | n/a | n/a | -CN¥251m |
| Jun 30 2023 | n/a | n/a | -CN¥327m |
| Mar 31 2023 | n/a | n/a | -CN¥405m |
| Dec 31 2022 | CN¥14m | CN¥7m | -CN¥484m |
| Sep 30 2022 | n/a | n/a | -CN¥1b |
| Jun 30 2022 | n/a | n/a | -CN¥2b |
| Mar 31 2022 | n/a | n/a | -CN¥3b |
| Dec 31 2021 | CN¥65m | CN¥37m | -CN¥4b |
| Sep 30 2021 | n/a | n/a | -CN¥4b |
| Jun 30 2021 | n/a | n/a | -CN¥4b |
| Mar 31 2021 | n/a | n/a | -CN¥3b |
| Dec 31 2020 | CN¥22m | CN¥5m | -CN¥1b |
| Dec 31 2019 | CN¥20m | CN¥4m | -CN¥521m |
Compensation vs Market: Zhi's total compensation ($USD1.82M) is above average for companies of similar size in the US market ($USD642.98K).
Compensation vs Earnings: Zhi's compensation has been consistent with company performance over the past year.
CEO
Zhi Hong (63 yo)
Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board Since March 24, 2021, Chief Executive Officer & Executive Director since February 23, 2018....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 8.3yrs | CN¥12.32m | 4.68% $ 4.4m | |
| COO, Joint Secretary & Executive Director | 5.2yrs | CN¥7.57m | 0.24% $ 227.4k | |
| Chief Technology Officer | 3.8yrs | no data | no data | |
| Chief Scientific Officer | 2.4yrs | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| Chief People Officer & Head of Human Resources | 4.4yrs | no data | no data | |
| Head of Pre-clinical Sciences and Translational Research | 8.2yrs | no data | no data | |
| Chief Medical Officer | 5.7yrs | no data | no data | |
| Head of China Development | less than a year | no data | no data | |
| Joint Company Secretary | no data | no data | no data |
Experienced Management: BRIB.F's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-founder | 8.3yrs | CN¥12.32m | 4.68% $ 4.4m | |
| COO, Joint Secretary & Executive Director | 3.8yrs | CN¥7.57m | 0.24% $ 227.4k | |
| Independent Non-executive Director | 5yrs | CN¥714.00k | 0.012% $ 11.3k | |
| Independent Non-executive Director | 5yrs | CN¥714.00k | 0.012% $ 11.3k | |
| Independent Non-Executive Director | 3.8yrs | CN¥344.00k | 0.045% $ 42.6k | |
| Independent Non-executive Director | 4.9yrs | CN¥714.00k | 0.012% $ 11.3k | |
| Independent Non-executive Director | 5yrs | CN¥714.00k | 0.012% $ 11.3k |
Experienced Board: BRIB.F's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 08:36 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Brii Biosciences Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangbin Zhou | China International Capital Corporation Limited |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Sean Wu | Morgan Stanley |